Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Published:2024-06-04 Issue:6 Volume:12 Page:122
ISSN:2079-9721
Container-title:Diseases
language:en
Short-container-title:Diseases

Author:

Kumada Naotaka¹²^ORCID,Iinuma Koji¹^ORCID,Kubota Yasuaki³,Takagi Kimiaki⁴^ORCID,Nakano Masahiro⁵,Ishida Takashi⁶,Yokoi Shigeaki⁷,Sugino Fumiya¹,Kawase Makoto¹^ORCID,Takeuchi Shinichi¹,Kawase Kota¹,Kato Daiki¹,Takai Manabu¹,Tobisawa Yuki¹,Ito Takayasu⁸,Nakane Keita¹,Koie Takuya¹^ORCID

Affiliation:

1. Department of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan

2. Department of Urology, Matsunami General Hospital, 185-1 Kasamatsucho, Hashima-gun, Gifu 501-6062, Japan

3. Department of Urology, Toyota Memorial Hospital, 1-1 Heiwacho, Toyota 471-8513, Japan

4. Department of Urology, Daiyukai Hospital, 1-9-9 Sakura, Ichinomiya 491-8551, Japan

5. Department of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noisiki, Gifu 500-8717, Japan

6. Department of Urology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu 500-8513, Japan

7. Department of Urology, Central Japan International Medical Center, Minokamo 505-8510, Japan

8. Center for Clinical Training and Career Development, Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan

Abstract

In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic renal cell carcinoma (mRCC). This retrospective multicenter cohort study enrolled patients with mRCC who received systemic therapy at six institutions between May 2005 and May 2023. The patients were divided into those who did not undergo CN (Group I) and those who underwent CN (Group II). The primary endpoints were oncological outcomes, including cancer-specific survival (CSS) and progression-free survival (PFS). Altogether, 137 patients with mRCC were included in this study. The median CSS was 14 months in Group I and 32 months in Group II (p < 0.001). Additionally, the median PFS in Groups I and II was 5 and 13 months, respectively (p = 0.006). A multivariate analysis showed that CN was an independent prognostic factor for CSS and PFS. Hence, CN is a potential treatment modality that can improve oncological outcomes in patients with mRCC.

Funder

Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science

Publisher

MDPI AG

Link

https://www.mdpi.com/2079-9721/12/6/122/pdf

Reference45 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies;Claeys;Urol. Oncol.,2017

3. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma;Bex;Eur. Urol. Oncol.,2019

4. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial;Motzer;J. Immunother. Cancer,2020

5. Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma;Choueiri;Ann. Oncol.,2020